ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2026
Who will be our adult congenital heart disease patient tomorrow?
Article in European heart journal supplements : journal of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Empowering congenital heart disease treatment: Physical activity prescription. The Italian proposal.International journal of cardiology. Congenital heart disease · 2026Article
- Wearable Cardioverter-Defibrillator in Adult Congenital Heart Disease: A Bridge to Decision, Recovery, and Advanced Therapies.Heart failure reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in paediatric cardiology and surgery have transformed congenital heart disease from a fatal condition into a chronic, lifelong one. As a result, the adult congenital heart disease (ACHD) population is rapidly expanding and aging, with rising medical complexity and growing workforce shortages. The ACHD patient of tomorrow will present with diverse needs-ranging from management of complex congenital repairs and heart failure (HF) to acquired comorbidities typical of aging populations. This shift necessitates a reimagined model of care emphasizing accessibility, precision, and patient partnership. Telemedicine, remote monitoring, and digital health platforms will decentralize ACHD care, improving follow-up and reducing disparities. Precision medicine, integrating genomics, proteomics, metabolomics, and microbiomics, will enable individualized diagnosis and therapy. Artificial intelligence (AI) will enhance early detection, risk prediction, and surgical planning while supporting patient education and engagement. Future ACHD patients will be empowered participants in shared decision-making, supported by AI-driven tools and online communities. Personalized strategies for HF management, especially in Fontan circulation and systemic right ventricles, along with advances in transcatheter interventions, will minimize surgical trauma and improve quality of life. Equally, mental health and social integration will be central to holistic care. Ultimately, tomorrow's ACHD care will merge technology and humanity-leveraging innovation to deliver compassionate, individualized treatment across a patient's lifespan.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.